The Journal of the Association of Physicians of Tamil Nadu Issue 3

Insulin Resistance in T2DM – Focus on Lobeglitazone

Unlock Image Open Access
Unlock Image Volume 2, Issue 3 ,  September 2023 ,  Pages 1-4
image representing clock
The journal is published as a quarterly issue.
VIEW PDF DOWNLOAD PDF
Downloads: 4
Views: 7

AUTHOR

Dr. Vijay Viswanathan1

1 –  Head and Chief Diabetologist, M. V. Hospital for Diabetes & Prof. M. Viswanathan Diabetes Research Centre, Chennai.

HISTORY

Available Online: September 2023

ABSTRACT

Insulin resistance (IR) is a key underlying pathophysiology in type 2 diabetes mellitus (T2DM). Thiazolidinediones (TZDs) are oral antidiabetic drugs (OADs) that can address IR. However, their use has been limited due to the associated adverse effects. A novel TZD – Lobeglitazone – has been introduced, which is a dual agonist of peroxisome proliferator-activated receptor (PPAR) and has been reported to have a favorable safety and efficacy profile. This paper summarizes some key characteristics of this agent and the findings from two recent studies conducted in Korea and India.

KEYWORDS

Type 2 diabetes mellitus, Lobeglitazone, insulin resistance

OPEN ACCESS

This work is licensed under the Creative Commons Attribution 4.0 International License.

https://creativecommons.org/licenses/by/4.0

COPYRIGHT

© 2023 Dr. Vijay Viswanathan, published by Association of Physicians of India-Tamilnadu State Chapter

Cite this Article: